Small-Molecule Inhibitors of TIPE3 Protein Identified through Deep Learning Suppress Cancer Cell Growth In Vitro

Xiaodie Chen1,2, Zhen Lu1, Jin Xiao3

  • 1Center for Cancer Immunology, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.

Cells
|May 10, 2024
PubMed

Insights

Researchers identified novel small-molecule inhibitors targeting Tumor Necrosis Factor-α-Induced Protein 8-Like 3 (TIPE3), a protein promoting cancer growth. Three compounds demonstrated significant anti-tumor effects in vitro, with two showing selective toxicity towards cancer cells, offering promising avenues for new cancer therapies.

Area of Science:

  • Oncology
  • Computational Chemistry
  • Drug Discovery

Background:

  • Tumor necrosis factor-α-induced protein 8-like 3 (TIPE3) is upregulated in various human cancers, promoting tumor proliferation, migration, invasion, and inhibiting apoptosis.
  • Targeting TIPE3 is a potential anti-cancer strategy.
  • Artificial intelligence (AI) is accelerating anti-cancer drug development.

Purpose of the Study:

  • To identify novel inhibitors of TIPE3 using a combination of computational methods.
  • To evaluate the in vitro anti-tumor activity of identified compounds.
  • To investigate the selectivity and molecular interactions of potential drug candidates.

Main Methods:

  • Utilized deep learning (DFCNN, DeepBindBC), molecular docking (Autodock Vina), and molecular dynamics (MD, metadynamics) for virtual screening.
  • Screened a ZINC compound dataset against TIPE3.
  • Selected six candidates for experimental validation, focusing on three promising compounds.

Main Results:

  • Three small-molecule compounds (K784-8160, E745-0011, 7238-1516) exhibited significant in vitro anti-tumor activity, reducing viability, proliferation, and migration while enhancing apoptosis.
  • Compounds E745-0011 and 7238-1516 demonstrated selective cytotoxicity against TIPE3-high expressing tumor cells, sparing normal cells.
  • Molecular docking confirmed interactions between the inhibitors and TIPE3, revealing key hydrophobic interactions and residues.

Conclusions:

  • AI-driven drug discovery, integrating deep learning and MD simulations, is effective for identifying TIPE3 inhibitors.
  • The identified compounds show significant potential for developing new anti-cancer therapeutics targeting TIPE3.
  • Further research into these selective inhibitors could lead to novel cancer treatments.